These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 10555993

  • 1. Effect of graft-versus-host disease (GVHD) on host hematopoietic progenitor cells is mediated by Fas-Fas ligand interactions but this does not explain the effect of GVHD on donor cells.
    Iwasaki T, Hamano T, Saheki K, Kuroiwa T, Kataoka Y, Takemoto Y, Ogata A, Sugihara A, Terada N, Fujimoto J, Kakishita E.
    Cell Immunol; 1999 Oct 10; 197(1):30-8. PubMed ID: 10555993
    [Abstract] [Full Text] [Related]

  • 2. Graft-versus-host-disease-associated donor cell engraftment in an F1 hybrid model is dependent upon the Fas pathway.
    Iwasaki T, Hamano T, Saheki K, Kuroiwa T, Kataoka Y, Takemoto Y, Ogata A, Fujimoto J, Kakishita E.
    Immunology; 2000 Jan 10; 99(1):94-100. PubMed ID: 10651946
    [Abstract] [Full Text] [Related]

  • 3. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
    Shustov A, Nguyen P, Finkelman F, Elkon KB, Via CS.
    J Immunol; 1998 Sep 15; 161(6):2848-55. PubMed ID: 9743345
    [Abstract] [Full Text] [Related]

  • 4. Expression of Fas and Fas-ligand in donor hematopoietic stem and progenitor cells is dissociated from the sensitivity to apoptosis.
    Pearl-Yafe M, Yolcu ES, Stein J, Kaplan O, Shirwan H, Yaniv I, Askenasy N.
    Exp Hematol; 2007 Oct 15; 35(10):1601-12. PubMed ID: 17889725
    [Abstract] [Full Text] [Related]

  • 5. Fas ligand enhances hematopoietic cell engraftment through abrogation of alloimmune responses and nonimmunogenic interactions.
    Pearl-Yafe M, Yolcu ES, Stein J, Kaplan O, Yaniv I, Shirwan H, Askenasy N.
    Stem Cells; 2007 Jun 15; 25(6):1448-55. PubMed ID: 17363551
    [Abstract] [Full Text] [Related]

  • 6. Mice deficient in fas ligand (gld) or fas (lpr) show few alterations in granulopoiesis.
    Fecho K, Bentley SA, Cohen PL.
    Cell Immunol; 1998 Aug 25; 188(1):19-32. PubMed ID: 9743554
    [Abstract] [Full Text] [Related]

  • 7. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z, Shatry A, Deyev V, Podack E, Mammolenti M, Blazar BR, Yagita H, Levy RB.
    Biol Blood Marrow Transplant; 2005 Aug 25; 11(8):576-86. PubMed ID: 16041307
    [Abstract] [Full Text] [Related]

  • 8. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect.
    Imado T, Iwasaki T, Kuroiwa T, Sano H, Hara H.
    Transplantation; 2004 Feb 15; 77(3):391-8. PubMed ID: 14966413
    [Abstract] [Full Text] [Related]

  • 9. Up-regulation of Fas and the costimulatory molecules B7-1 and B7-2 on peripheral lymphocytes in autoimmune B6/gld mice.
    Weintraub JP, Eisenberg RA, Cohen PL.
    J Immunol; 1997 Oct 15; 159(8):4117-26. PubMed ID: 9379003
    [Abstract] [Full Text] [Related]

  • 10. A major role for the Fas pathway in acute graft-versus-host disease.
    Via CS, Nguyen P, Shustov A, Drappa J, Elkon KB.
    J Immunol; 1996 Dec 15; 157(12):5387-93. PubMed ID: 8955186
    [Abstract] [Full Text] [Related]

  • 11. Involvement of Fas-mediated apoptosis in the hematopoietic progenitor cells of graft-versus-host reaction-associated myelosuppression.
    Mori T, Nishimura T, Ikeda Y, Hotta T, Yagita H, Ando K.
    Blood; 1998 Jul 01; 92(1):101-7. PubMed ID: 9639505
    [Abstract] [Full Text] [Related]

  • 12. Fas cross-linking mimics the inhibitory effect of anti-CD3 on IL-3-induced histamine and cytokine production by murine myeloid spleen cell precursors.
    Ben Amor A, Schneider E, Arnould A, Machavoine F, Dy M.
    Exp Hematol; 1998 Aug 01; 26(9):903-9. PubMed ID: 9694512
    [Abstract] [Full Text] [Related]

  • 13. [Selected elimination of mouse alloreactive T cells by Fas-FasL passway].
    Liu L, Zou P, Xu Z, Hu Z, Chen Y, Song S.
    Zhonghua Xue Ye Xue Za Zhi; 2002 Apr 01; 23(4):187-90. PubMed ID: 12133454
    [Abstract] [Full Text] [Related]

  • 14. The effect on the proliferation and apoptosis of alloreactive T cells of cell dose in a murine MHC-mismatched hematopoietic cell transplantation model.
    Fujioka T, Taniguchi Y, Masuda T, Nishida S, Ikegame K, Kawakami M, Tsuboi A, Hosen N, Murakami M, Oji Y, Oka Y, Sugiyama H, Kawase I, Ogawa H.
    Transpl Immunol; 2003 Apr 01; 11(2):187-95. PubMed ID: 12799203
    [Abstract] [Full Text] [Related]

  • 15. Fas-mediated liver damage in MRL hemopoietic chimeras undergoing lpr-mediated graft-versus-host disease.
    Bobé P, Bonardelle D, Reynès M, Godeau F, Mahiou J, Joulin V, Kiger N.
    J Immunol; 1997 Nov 01; 159(9):4197-204. PubMed ID: 9379013
    [Abstract] [Full Text] [Related]

  • 16. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
    Li Y, Guo K, Chen Y, Song Z, Li J, Deng L.
    Zhonghua Xue Ye Xue Za Zhi; 2002 Aug 01; 23(8):411-4. PubMed ID: 12411044
    [Abstract] [Full Text] [Related]

  • 17. Inflammatory arthropathy in MRL hematopoietic chimeras undergoing Fas mediated graft-versus-host syndrome.
    Bonardelle D, Bobé P, Reynès M, Amouroux J, Tricottet V, Godeau F, Kiger N.
    J Rheumatol; 2001 May 01; 28(5):956-61. PubMed ID: 11361222
    [Abstract] [Full Text] [Related]

  • 18. Short-term myeloid reconstitution following TBI is not adversely affected by doses of FK506 that abrogate lethal GVHD.
    Cooper MH, Patrene KD, Vecchini F, Austin CA, Markus PM, Boggs SS.
    Bone Marrow Transplant; 1994 Sep 01; 14(3):355-62. PubMed ID: 7527689
    [Abstract] [Full Text] [Related]

  • 19. A metalloproteinase inhibitor prevents acute graft-versus-host disease in mice after bone marrow transplantation.
    Hattori K, Hirano T, Ushiyama C, Miyajima H, Yamakawa N, Ikeda S, Yoshino K, Tateno M, Oshimi K, Kayagaki N, Yagita H, Okumura K.
    Bone Marrow Transplant; 1999 Jun 01; 23(12):1283-9. PubMed ID: 10414917
    [Abstract] [Full Text] [Related]

  • 20. Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease.
    Georgantas RW, Bohana-Kashtan O, Civin CI.
    Transplantation; 2006 Aug 27; 82(4):471-8. PubMed ID: 16926590
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.